U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Na.H2O4P
Molecular Weight 120.9772
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM PHOSPHATE P-32, UNSPECIFIED

SMILES

[Na+].O[32P](O)([O-])=O

InChI

InChIKey=AJPJDKMHJJGVTQ-ZYUMTRPDSA-M
InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1/i;5+1

HIDE SMILES / InChI

Molecular Formula H2O4P
Molecular Weight 97.9874
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
PubMed

PubMed

TitleDatePubMed
The use of radioactive phosphorus in the diagnosis of thyroid cancer.
1961 Nov
Substance Class Chemical
Created
by admin
on Sat Dec 16 03:59:16 GMT 2023
Edited
by admin
on Sat Dec 16 03:59:16 GMT 2023
Record UNII
FEB963GEFV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM PHOSPHATE P-32, UNSPECIFIED
Common Name English
SODIUM PHOSPHATE, LABELED WITH PHOSPHORUS-32
Common Name English
SODIUM PHOSPHATE P-32 (INDEFINITE STOICHIOMETRY)
Common Name English
PHOSPHORIC ACID, SODIUM SALT, RADIOACTIVE
Common Name English
PHOSPHORIC-32P ACID, SODIUM SALT
Common Name English
SODIUM RADIOPHOSPHATE (P32)
Common Name English
SODIUM PHOSPHATE, RADIOACTIVE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1446
Created by admin on Sat Dec 16 03:59:16 GMT 2023 , Edited by admin on Sat Dec 16 03:59:16 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C185463
Created by admin on Sat Dec 16 03:59:16 GMT 2023 , Edited by admin on Sat Dec 16 03:59:16 GMT 2023
PRIMARY
CAS
8027-28-9
Created by admin on Sat Dec 16 03:59:16 GMT 2023 , Edited by admin on Sat Dec 16 03:59:16 GMT 2023
PRIMARY
FDA UNII
FEB963GEFV
Created by admin on Sat Dec 16 03:59:16 GMT 2023 , Edited by admin on Sat Dec 16 03:59:16 GMT 2023
PRIMARY
PUBCHEM
23694678
Created by admin on Sat Dec 16 03:59:16 GMT 2023 , Edited by admin on Sat Dec 16 03:59:16 GMT 2023
PRIMARY